Correction
for
Mikolajczyk et al., Obstet Gynecol 111 (2) 413-419.
Correction
for
Schoner et al., Obstet Gynecol 111 (2) 483-486.
Correction
for
Ducarme et al., Obstet Gynecol 111 (2) 535-537.
Correction
for
Van Wyck et al., Obstet Gynecol 110 (2) 267-278.
Obstetrics & Gynecology 2008;111:996
© 2008 by The American College of Obstetricians and Gynecologists
Corrections
In "Evaluation of Logistic Regression Reporting in Current Obstetrics and Gynecology Literature" by R. T. Mikolajczyk, A. DiSilvesto, and J. Zhang (Obstet Gynecol 2008;111:413–9), the second author’s last name is misspelled. The correct spelling is DiSilvestro. The authors regret this error.
In "Intravenous Ferric Carboxymaltose Compared With Oral Iron in the Treatment of Postpartum Anemia: A Randomized Controlled Trial" by D. B. Van Wyck, M. G. Martens, M. H. Seid, J. B. Baker, and A. Mangione (Obstet Gynecol 2007;110:267–78), an incorrect version of Figure 2 was published (page 271). The corrected figure appears here. The authors regret this error.
View larger version (11K):
[in this window]
[in a new window]
|
Fig. 2. Percentage of study participants achieving anemia endpoints according to treatment assignment (IV ferric carboxymaltose given on days 0, 7, or 14 or oral ferrous sulfate thrice daily on days 0–42). A. Primary study endpoint, Hb increase 2 g/dL or more. B. Secondary endpoint, Hb increase 3.0 g/dL or more. C. Secondary endpoint, achieved Hb 12.0 g/dL or more. Between-group comparisons: *P<.05; **P<.01; ***P<.001. Solid line with circle, intravenous ferric carboxymaltose; solid line with triangle, oral ferrous sulfate.
Van Wyck. IV Ferric Carboxymaltose for Postpartum Anemia. Obstet Gynecol 2007.
|
|
In "Postpartum Thrombosis of the Superior Mesenteric Artery After Vaginal Delivery" by G. Ducarme, O. Lidove, A. Leduey, A. Geffroy, Y. Panis, Y. Castier, and D. Luton (Obstet Gynecol 2008;111:535–37), the order of the authors is incorrect. The correct order is Guillaume Ducarme, Olivier Lidove, Alexandre Leduey, Arnaud Geffroy, Yves Panis, Dominique Luton, and Yves Castier. The authors regret this error.
In "Severe Facial Clefts in Acrofacial Dysostosis: A Consequence of Prenatal Exposure to Mycophenolate Mofetil? by K. Schoner, J. Steinhard, J. Figiel, and H. Rehder (Obstet Gynecol 2008;111:483–6), a correction the author provided was omitted from page 484, second sentence, second paragraph, of the Comment section. The correct sentence is "They concern a preterm infant with hypoplastic nails and short fifth fingers (mycophenolate mofetil given after renal transplantation to the mother during pregnancy at 6–7 weeks of gestation); a fetus with cleft lip and palate, hypertelorism, ear anomalies, micrognathia, and absent corpus callosum (mycophenolate mofetil after renal transplantation until 14 weeks of gestation), in which the possibility of an underlying autosomal-recessive hypertelorism-microtia-clefting syndrome had not been considered; and a newborn with bilateral ear anomalies, hypertelorism, and cleft palate (mycophenolate mofetil until 8 weeks of gestation because of lupus nephritis).5–7,10" The publisher regrets this error.
doi:10.1097/AOG.0b013e31816bfd97
